The European markets have been navigating a landscape marked by geopolitical tensions and fluctuating energy prices, with the pan-European STOXX Europe 600 Index showing modest gains. Amidst this backdrop, investors are increasingly looking at diverse investment avenues to capitalize on potential opportunities. Penny stocks, often representing smaller or newer companies, remain an intriguing area for those seeking growth at lower price points. Although the term might seem outdated, these stocks can still offer significant upside when backed by strong financials and solid fundamentals.
Name
Share Price
Market Cap
Financial Health Rating
Ariston Holding (BIT:ARIS)
€3.576
€1.24B
★★★★★★
Orthex Oyj (HLSE:ORTHEX)
€4.61
€81.87M
★★★★★★
Lucisano Media Group (BIT:LMG)
€1.15
€17.08M
★★★★★☆
Angler Gaming (NGM:ANGL)
SEK3.60
SEK269.95M
★★★★★★
Angler Gaming (DB:0QM)
€0.31
€244.45M
★★★★★★
Verkkokauppa.com Oyj (HLSE:VERK)
€3.27
€147.41M
★★★★★☆
Abak (WSE:ABK)
PLN5.00
PLN13.47M
★★★★★★
High (ENXTPA:HCO)
€3.40
€65.9M
★★★★★★
Esprinet (BIT:PRT)
€4.86
€240.29M
★★★★★★
Deceuninck (ENXTBR:DECB)
€1.99
€275.06M
★★★★★★
Click here to see the full list of 295 stocks from our European Penny Stocks screener.
Let’s take a closer look at a couple of our picks from the screened companies.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Hamlet BioPharma AB (publ) is a Swedish company focused on developing drugs for cancer treatment and prevention, with a market cap of €1.37 billion.
Operations: Hamlet BioPharma AB (publ) has not reported any revenue segments.
Market Cap: €1.37B
Hamlet BioPharma is a pre-revenue company focused on cancer treatment development, with recent strategic moves including a non-binding Letter of Intent for global commercialization of its bladder cancer drug, Alpha 1H. Despite its €1.37 billion market cap, the company faces challenges such as increasing losses and high share price volatility. Hamlet has less than one year of cash runway and remains debt-free, with short-term assets covering liabilities. The collaboration with ImmunoForge aims to enhance drug delivery technology for tuberculosis treatment, potentially expanding future revenue streams if commercial agreements are successfully executed.
DB:7ZT Financial Position Analysis as at Mar 2026
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: ABIONYX Pharma SA is a biotech company focused on discovering and developing therapies for renal and ophthalmological diseases, with a market cap of €131.06 million.
Story Continues
Operations: ABIONYX Pharma SA has not reported any revenue segments.
Market Cap: €131.06M
ABIONYX Pharma, with a market cap of €131.06 million, is advancing in the biotech sector with a focus on renal and ophthalmological therapies. The company recently announced a breakthrough in synthetic sphingomyelin production, enhancing its CER-001 therapeutic platform for sepsis treatment. Despite reporting €4.1 million in sales for 2025, ABIONYX remains unprofitable and faces declining earnings forecasts over the next three years. Its cash runway extends beyond one year after recent capital raises, though share price volatility persists. The company’s strategic innovation positions it to overcome technological barriers and potentially form partnerships within the industry.
ENXTPA:ABNX Financial Position Analysis as at Mar 2026
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Enzymatica AB (publ) is a life science company that develops and sells medical devices for infection-related diseases, with a market cap of SEK604.41 million.
Operations: The company generates revenue from its medical devices segment, totaling SEK53.90 million.
Market Cap: SEK604.41M
Enzymatica AB, with a market cap of SEK604.41 million, continues to face challenges as an unprofitable entity in the life sciences sector. Recent financials show sales of SEK53.9 million for 2025, an improvement from the previous year, yet net losses remain substantial at SEK51.89 million. The company’s financial position is strained with less than a year of cash runway and ongoing high share price volatility over recent months. However, Enzymatica’s short-term assets comfortably exceed both its short-term and long-term liabilities, providing some stability amidst leadership changes with the recent appointment of a new CEO, Sana Alajmovic.
OM:ENZY Financial Position Analysis as at Mar 2026
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DB:7ZT ENXTPA:ABNX and OM:ENZY.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com